AI heart scan could replace costly MRI for chemo patients
NCT ID NCT07093918
First seen Nov 18, 2025 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This study will test whether artificial intelligence-enhanced 3D and 2D echocardiography (ultrasound) can detect heart damage caused by chemotherapy as accurately as cardiac MRI. Researchers will compare these AI methods with standard ultrasound and MRI in 120 adults who have received potentially heart-harming chemotherapy. If successful, the AI approach could offer a faster, cheaper, and more accessible way to monitor heart health during cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOTOXICITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
V-echo and L-echo (AI-enhanced 3D and 2D echocardiography imaging systems)
What this could lead to
If successful, this could offer a quicker, more accessible way to monitor heart health in chemotherapy patients, potentially replacing more expensive MRI scans.
What could go wrong
This is an early-stage diagnostic accuracy study with only 120 participants. The AI methods may not prove as reliable as MRI, and results may not apply to all patient groups.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.